Dublin, Jan. 11, 2017 (GLOBE NEWSWIRE) — Research and Markets has announced the addition of the “Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027” report to their offering.
Hepatitis C is a single-stranded RNA virus that infects and damages the liver. In most cases, hepatitis C causes no noticeable symptoms until the liver has been significantly damaged. Symptoms are often vague such as flu-like muscle aches and fatigue.
This report provides the current prevalent population for Chronic Hepatitis C across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, Russia, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Chronic Hepatitis C have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Chronic hepatitis C is most often associated with co-infections with other chronic viral infections including:
– HIV Co-infection
– HBV Co-infection
– HCV co-infection
Likely downstream events associated with chronic HCV infection include:
– Cirrhosis of the liver
– Hepatocellular carcinoma
– Excess mortality associated with liver disease / decompensated liver function
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Chronic Hepatitis C
10. Genotype of HCV infection in Chronic Hepatitis C patients
10.1 Predominant Genotype
11. Main route of infection for Chronic HCV patients
12. Major viral co-infection in Chronic HCV patients
13. Access to healthcare for CHCV patients
14. Events and outcomes for CHCV patients
15. Abbreviations used in the report
16. Patient-Based Offering
17. Online Pricing Data and Platforms
18. References
19. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/qfbs47/chronic_hepatitis
CONTACT:
CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs
